Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Daratumumab: a necessary addition to the standard of care for MM?

Katja J. Weisel, MD, from The University Hospital of Tübingen, Tübingen, Germany, evaluates the effectiveness of administering daratumumab, a safe and well-tolerated monoclonal antibody, to the standard regimen of care for treating relapsed or refractory multiple myeloma. She reports that in previous clinical trials, MM patients who had only received one treatment line prior to daratumumab therapy were found to benefit more from treatment (NCT02076009) (NCT02136134), which suggests that daratumumab therapy may be more effective if administered earlier to patients. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.